Immunome, Inc.

XNASHealth care

Last traded price · USD

$17.74

−9.14%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $19.38
Previous close: $19.52
Volume: 509,530
Day's high: $19.41
Day's low: $17.73

In brief

Immunome, Inc. is a health care company listed on Nasdaq, valued at about $2.09B.
Its shares closed at $19.52 on 4 Nov 2026, up 26.7% over the past year.
From India you can buy IMNM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunome, Inc. (IMNM) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole IMNM share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade IMNM options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +1.1% (SPY −1.6%, XLV +13.5%). 3 months: −23.5% (SPY −0.4%, XLV +15.5%). 1 year: +26.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMNM, SPY and XLV · as of 4 Nov 2026
12.2 days to cover short interest
17.3M shares were sold short at the 15 Oct 2026 settlement, 15.2% of the 113.6M shares outstanding; covering them would take 12.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $19.52 was 10.9% below its 50-day average ($21.91) and 13.0% below its 200-day average ($22.44). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 30 Oct 2026, 3 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 3.5M shares was 2.3× the average of the 30 sessions before it (1.5M), as the price fell 3.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
32% of the way up its 52-week range
Closed at $19.52 on 4 Nov 2026: 35.1% below the 52-week high of $30.06 (19 Aug 2026) and 33.3% above the low of $14.64 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.1%

6 months−16.1%

1 year+26.7%

5 years−13.8%

Newswire

About

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Website

Notable moves

February 6, 2024
+36.91%
January 3, 2023
+47.51%
March 18, 2022
+30.79%

Newswire

About

Website

Notable moves

February 6, 2024
+36.91%
January 3, 2023
+47.51%
March 18, 2022
+30.79%

Immunome, Inc.

XNASHealth care

Last traded price · USD

$17.74

−9.14%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $19.38
Previous close: $19.52
Volume: 509,530
Day's high: $19.41
Day's low: $17.73

In brief

Immunome, Inc. is a health care company listed on Nasdaq, valued at about $2.09B.
Its shares closed at $19.52 on 4 Nov 2026, up 26.7% over the past year.
From India you can buy IMNM in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Immunome, Inc. (IMNM) shares from India?

Do I need the price of a whole IMNM share to invest?

How much can I invest in US stocks in a year?

Can I trade IMNM options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, behind its sector fund XLV over 1 year
1 month: +1.1% (SPY −1.6%, XLV +13.5%). 3 months: −23.5% (SPY −0.4%, XLV +15.5%). 1 year: +26.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: IMNM, SPY and XLV · as of 4 Nov 2026
12.2 days to cover short interest
17.3M shares were sold short at the 15 Oct 2026 settlement, 15.2% of the 113.6M shares outstanding; covering them would take 12.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $19.52 was 10.9% below its 50-day average ($21.91) and 13.0% below its 200-day average ($22.44). It has closed below the 200-day for 30 sessions, since 24 Sep 2026. The 50-day average crossed below the 200-day on 30 Oct 2026, 3 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Volume 2.3× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 3.5M shares was 2.3× the average of the 30 sessions before it (1.5M), as the price fell 3.9%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
32% of the way up its 52-week range
Closed at $19.52 on 4 Nov 2026: 35.1% below the 52-week high of $30.06 (19 Aug 2026) and 33.3% above the low of $14.64 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+1.1%

6 months−16.1%

1 year+26.7%

5 years−13.8%

Newswire

About

Website

Notable moves

February 6, 2024
+36.91%
January 3, 2023
+47.51%
March 18, 2022
+30.79%

Newswire

About

Website

Notable moves

February 6, 2024
+36.91%
January 3, 2023
+47.51%
March 18, 2022
+30.79%

Immunome, Inc.

Immunome, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

12.2 days to cover short interest

Below its 50- and 200-day averages

Volume 2.3× its 30-session average on 4 Nov 2026

32% of the way up its 52-week range

Immunome, Inc.

Immunome, Inc. in brief

Ahead of SPY, behind its sector fund XLV over 1 year

12.2 days to cover short interest

Below its 50- and 200-day averages

Volume 2.3× its 30-session average on 4 Nov 2026

32% of the way up its 52-week range